1. Home
  2. ALT vs RIGL Comparison

ALT vs RIGL Comparison

Compare ALT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • RIGL
  • Stock Information
  • Founded
  • ALT 1997
  • RIGL 1996
  • Country
  • ALT United States
  • RIGL United States
  • Employees
  • ALT N/A
  • RIGL N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALT Health Care
  • RIGL Health Care
  • Exchange
  • ALT Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • ALT 292.0M
  • RIGL 335.5M
  • IPO Year
  • ALT N/A
  • RIGL 2000
  • Fundamental
  • Price
  • ALT $3.83
  • RIGL $38.85
  • Analyst Decision
  • ALT Strong Buy
  • RIGL Buy
  • Analyst Count
  • ALT 6
  • RIGL 5
  • Target Price
  • ALT $17.40
  • RIGL $38.20
  • AVG Volume (30 Days)
  • ALT 3.0M
  • RIGL 995.6K
  • Earning Date
  • ALT 08-12-2025
  • RIGL 08-05-2025
  • Dividend Yield
  • ALT N/A
  • RIGL N/A
  • EPS Growth
  • ALT N/A
  • RIGL N/A
  • EPS
  • ALT N/A
  • RIGL 5.43
  • Revenue
  • ALT $20,000.00
  • RIGL $267,921,000.00
  • Revenue This Year
  • ALT N/A
  • RIGL $59.93
  • Revenue Next Year
  • ALT $761,880.20
  • RIGL N/A
  • P/E Ratio
  • ALT N/A
  • RIGL $7.15
  • Revenue Growth
  • ALT N/A
  • RIGL 105.62
  • 52 Week Low
  • ALT $2.90
  • RIGL $12.66
  • 52 Week High
  • ALT $11.16
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • RIGL 68.57
  • Support Level
  • ALT $3.35
  • RIGL $39.00
  • Resistance Level
  • ALT $3.66
  • RIGL $42.08
  • Average True Range (ATR)
  • ALT 0.19
  • RIGL 2.32
  • MACD
  • ALT 0.07
  • RIGL -0.37
  • Stochastic Oscillator
  • ALT 86.18
  • RIGL 53.26

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: